Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AMRX 
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AMRX (1-star) is a SELL. SELL since 3 days. Profits (-7.69%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.99% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.86B USD | Price to earnings Ratio - | 1Y Target Price 11.67 |
Price to earnings Ratio - | 1Y Target Price 11.67 | ||
Volume (30-day avg) 1993644 | Beta 1.05 | 52 Weeks Range 5.18 - 9.47 | Updated Date 03/31/2025 |
52 Weeks Range 5.18 - 9.47 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -4.18% | Operating Margin (TTM) 10.81% |
Management Effectiveness
Return on Assets (TTM) 6.24% | Return on Equity (TTM) -881.26% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 5061722999 | Price to Sales(TTM) 1.37 |
Enterprise Value 5061722999 | Price to Sales(TTM) 1.37 | ||
Enterprise Value to Revenue 1.81 | Enterprise Value to EBITDA 11.51 | Shares Outstanding 313382016 | Shares Floating 157819363 |
Shares Outstanding 313382016 | Shares Floating 157819363 | ||
Percent Insiders 48.68 | Percent Institutions 41.21 |
Analyst Ratings
Rating 4 | Target Price 10.5 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Amneal Pharmaceuticals, Inc. Class A Common Stock
Company Overview
History and Background
Amneal Pharmaceuticals, Inc. was founded in 2002. It quickly grew through organic development and acquisitions, becoming a major player in the generics industry. The company focuses on developing, manufacturing, and distributing a diverse range of pharmaceutical products.
Core Business Areas
- Generics: Focuses on developing, manufacturing and commercializing generic pharmaceutical products across a broad range of therapeutic areas and dosage forms.
- Specialty: Dedicated to innovative drug delivery and differentiated generics focused on complex generics and branded injectables.
- AvKARE: A subsidiary that focuses on institutional sales and distribution of pharmaceuticals, medical supplies, and equipment to government agencies and commercial customers.
Leadership and Structure
Nirav D. Patel and Chirag K. Patel serve as Co-Chief Executive Officers. The company has a standard corporate structure with a board of directors and various executive leadership positions overseeing different functional areas.
Top Products and Market Share
Key Offerings
- Levothyroxine Sodium: A common medication for hypothyroidism. Market share data varies, but Amneal is a significant player in the generic levothyroxine market. Competitors include Mylan (Viatris), Teva Pharmaceutical and Sandoz.
- Generic Injectables: Amneal's Specialty segment includes a portfolio of generic injectable products. Market share and revenue details are not typically disclosed for specific products, but this contributes significantly to Amneal's revenue. Competitors include Pfizer, Hikma, and Fresenius Kabi.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly generics, is characterized by intense competition, pricing pressure, regulatory scrutiny, and consolidation. Growth is driven by patent expirations and increasing demand for affordable medications.
Positioning
Amneal is positioned as a leading generics manufacturer with a growing specialty segment. Its competitive advantages include its diversified product portfolio, vertically integrated manufacturing capabilities, and strategic acquisitions. Focus is shifting towards higher margin generics and specialty injectables.
Total Addressable Market (TAM)
The global generics market is valued in the hundreds of billions of dollars. Amneal is positioned to capture a portion of this TAM through its product offerings and strategic initiatives. Specific TAM varies by product category, e.g., injectables and oral solids.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Vertically integrated manufacturing
- Strong generic development capabilities
- Growing specialty segment
- Experienced management team
Weaknesses
- High debt levels
- Exposure to pricing pressure in the generics market
- Reliance on successful ANDA approvals
- Complex regulatory environment
- Integration risks from acquisitions
Opportunities
- Further expansion in the specialty pharmaceutical market
- Strategic acquisitions to broaden product portfolio
- Increasing demand for affordable generics
- Entry into new international markets
- Development of biosimilars
Threats
- Increased competition from other generic manufacturers
- Regulatory changes impacting drug pricing
- Patent challenges and litigation
- Supply chain disruptions
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- MYL
Competitive Landscape
Amneal faces intense competition from established generic manufacturers. Its advantages include its diversified product portfolio and vertically integrated manufacturing. Disadvantages include high debt and exposure to pricing pressures.
Major Acquisitions
Alvotech
- Year: 2023
- Acquisition Price (USD millions): 62
- Strategic Rationale: To broaden Amneal's product portfolio of biosimilars.
Growth Trajectory and Initiatives
Historical Growth: Amneal's historical growth has been driven by a combination of organic development and acquisitions. Growth has fluctuated based on generic launches and market conditions.
Future Projections: Analyst projections vary. Key growth drivers include the specialty segment, successful ANDA approvals, and cost-cutting initiatives. Refer to analyst reports for specific revenue and earnings forecasts.
Recent Initiatives: Recent initiatives include focusing on high-value generics, expanding the specialty injectables portfolio, and improving operational efficiency.
Summary
Amneal Pharmaceuticals is a generics and specialty pharmaceutical company facing both opportunities and challenges. It has a diversified product portfolio and vertically integrated manufacturing, but carries high debt. Its focus on specialty injectables and cost optimization is a positive strategy. They need to watch out for competition and regulatory changes.
Similar Companies
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
VTRS
Viatris Inc
VTRS
Viatris Inc
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Investor Relations Materials, Analyst Reports, Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary depending on the source. Financial data should be verified with official SEC filings. All data is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Exchange NYSE | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2009-01-15 | Co-Founder, Co-CEO, President & Director Mr. Chirag K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8300 | Website https://www.amneal.com |
Full time employees 8300 | Website https://www.amneal.com | ||
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.